Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
2.22
USD
-1.77%
+13.27%
+26.14%
This article is reserved for members
Not a member ?
Free registration
Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing
08/05
MT
Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating
07/05
MT
Transcript : Corvus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024
07/05
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
07/05
CI
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
30/04
MT
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
10/04
CI
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating
20/03
MT
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2
20/03
MT
Transcript : Corvus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024
20/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
20/03
CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
20/03
CI
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
12/02
CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading
10/02
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
09/02
MT
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation
09/02
MT
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation
09/02
DJ
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer
07/02
CI
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors
24/01
CI
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
09/12
CI
Transcript : Corvus Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023
08/11
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
08/11
CI
Corvus Pharmaceuticals Says Preclinical Data Showed Soquelitinib Was Active in Six Inflammatory, Immune Disease Models
02/11
MT
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
02/11
CI
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
11/23/11
MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
07/23/07
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumorâs ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Companyâs third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
More about the company
Last Close Price
2.22
USD
Average target price
7.833
USD
Spread / Average Target
+252.85%
Consensus
1st Jan change
Capi.
+26.14% 11Cr +29.77% 4.95TCr +1.00% 4.26TCr +49.62% 4.25TCr -5.26% 2.91TCr +13.68% 2.66TCr -22.99% 1.86TCr +8.22% 1.32TCr +32.41% 1.25TCr +24.01% 1.21TCr
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**